Global cephalosporin drugs market projected to rise 3.34 percent
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
List view / Grid view
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
A complete response letter (CRL) has been sent to Dr Reddy’s for two generic products.
The CMA alleges that Aspen broke competition law, prompting the drug supplier to offer a payment and other compensations to the NHS.
In order keep up-to-date records and protect public health the FDA has announced it intends to deactivate out-of-date drug listings.
An Ebola clinical trial has been stopped early as Regeneron's REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.
The global alopecia treatment market is projected to exhibit a CAGR of 4.9 percent from 2018–2026.
Less than one-third of UK patient groups rate the reputation of the pharma industry as good or excellent.
The EMA has requested that liposomal medication names be changed to avoid the risk of confusion.
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
The rise of manufacturing advanced drugs will stimulate growth in the pharmaceutical chemical market.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
A fund of almost £450 million has been announced by the UK Government to mitigate drug shortages in the event of a no-deal Brexit.
A three-drug combination injection to treat patients with complicated urinary tract and intra-abdominal infections has been approved by the FDA.
The two Canadian provinces have expressed concern over the new draft regulations, claiming that the reforms would delay patient access to medicines.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.